Yield10 Researchers Publish Research in Plant Cell Reports Describing the Development of its Camelina Platform as a Model Cro...
21 June 2018 - 10:30PM
Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new
technologies to create step-change improvements in crop yield to
enhance global food security, today announced the publication of
research describing the development of its Camelina platform as a
model crop for novel yield trait discovery.
The research paper titled “Camelina sativa, an oilseed at the
nexus between model system and commercial crop” was published in
Plant Cell Reports, a monthly peer-reviewed journal featuring
articles on new advances in all aspects of plant cell science,
plant genetics and molecular biology. The authors document the use
of Camelina in a variety of research programs focused on improving
crop yield and suggest that if yields can improve significantly,
Camelina itself may be of interest as a commercial crop in the
future. Camelina has been explored for production of biofuels,
animal and aquaculture feed, specialty nutritional oils and other
uses.
The paper describes the approach Yield10 researchers have taken
to develop the Company’s Camelina platform and highlights the
advantages of utilizing the crop for novel trait development,
including short life cycle, ease of genetic transformation and
performance of the crop under field conditions.
The authors of the study also highlight the use of the Camelina
platform to evaluate yield performance of very complex novel
metabolic pathways to increase seed yield. The paper includes the
case study of the development and testing of multi-gene complex
carbon fixation pathways, derived from metabolic engineering
studies expressed by seed specific promoters. In greenhouse studies
in Camelina, the researchers observed large increases in seed yield
in engineered plants where the best plants produced seed yields of
approximately 2.2 times the control plants. Seed oil content was
also significantly increased, such that the total oil produced per
plant in the best plants reached 2.4 to 2.8 times the total oil
produced in the control plants. The weight of individual seeds in
the best plants was approximately 1.3 times the weight of
individual seeds in the control plants. The researchers noted that
such complex pathways cannot be stably engineered to create a
commercial plant line, however the work is important to understand
the potential for seed yield increases and to devise new solutions
to yield based on smaller gene sets.
“This research describes the approach we’ve taken to develop
Camelina sativa as a world-class platform for crop yield trait
discovery,” said Kristi Snell, Ph.D., Chief Science Officer at
Yield10 Bioscience, Inc. “In an early use of our Camelina platform,
we evaluated the yield performance of complex multi-gene carbon
fixation pathways derived from metabolic engineering studies.
Subsequently, we have used this system extensively in the ongoing
development and event selection for C3003, a novel yield trait gene
for C3 crops. In addition, we have recently deployed the platform
for screening novel oil content boosting traits created using
genome-editing. A key value of the platform is that it allows the
relatively rapid creation of plant events that can be tested in the
greenhouse and field tested under real-world conditions. Further,
new traits tested in our Camelina platform appear to perform as
predicted in early studies in canola, highlighting the potential
value of the system for trait development in major oilseed
crops.”
“Our early interest in exploring the theoretical limits of crop
yield led to the creation of complex microbial gene systems aimed
at boosting carbon capture in plants deployed using our Camelina
platform,” said Oliver Peoples, Ph.D., President and CEO of Yield10
Bioscience. “In greenhouse studies, we discovered that these
complex genetic systems can double seed yield and oil content in
Camelina. While such gene systems are far too complex to be
commercialized, the results provide important insights and allow us
to benchmark the limits of seed yield as well as inform our
advanced metabolic flux modeling, a core component of our GRAIN
computational trait gene discovery platform. This work also
suggests that the use of metabolic engineering to de-bottleneck
carbon flow in plants may lead to the development of novel systems
consisting of perhaps two to three yield trait genes that may
produce significant improvements to seed yield, and provide
meaningful advances toward achieving global food
security.”
The authors of the Plant Cell Reports paper include, Meghna R.
Malik, Jihong Tang, Nirmala Sharma, Claire Burkitt, Yuanyuan Ji,
Marie Mykytyshyn, Karen Bohmert-Tatarev, Oliver Peoples and Kristi
D. Snell, all of Yield10 Bioscience or Yield10’s wholly owned
Canadian subsidiary Metabolix Oilseeds, Inc.
About Yield10
Bioscience
Yield10 Bioscience, Inc. is focused on developing new
technologies to achieve step-change improvements in crop yield to
enhance global food security. Yield10 has an extensive track record
of innovation based around optimizing the flow of carbon in living
systems. Yield10 is leveraging its technology platforms and unique
knowledge base to design precise alterations to gene activity and
the flow of carbon in plants to produce higher yields with lower
inputs of land, water or fertilizer. Yield10 is advancing several
yield traits it has developed in crops such as Camelina, canola,
soybean and rice. Yield10 is headquartered in Woburn, MA and has an
Oilseeds Center of Excellence named Metabolix Oilseeds, located in
Saskatoon, Canada.
For more information about the company, please visit
www.yield10bio.com.
(YTEN-G)
Safe Harbor for Forward-Looking
Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, the use of technology to successfully identify targets
and develop systems for increasing crop yield, the potential of
Camelina as a commercial crop, the predictive value of the Camelina
platform, and progress by Yield10, constitute forward-looking
statements. Such forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to
differ materially from those anticipated, including the risks and
uncertainties detailed in Yield10 Bioscience's filings with the
Securities and Exchange Commission. Yield10 assumes no obligation
to update any forward-looking information contained in this press
release or with respect to the matters described herein.
Contacts: Yield10
Bioscience:Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Investor Relations: Amato and Partners,
LLCadmin@amatoandpartners.com
Media Inquiries: Eric FischgrundFischtank Marketing and
PReric@fischtankpr.com
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From May 2023 to May 2024